- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Giuseppe Saglio Compares Efficacy, Safety of Nilotinib With Imatinib for CML Patients
Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib's side effects are too much for patients.
Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib’s side effects are too much for patients, according to a study from Novartis presented at the 56th Annual Meeting of the American Society of Hematology.
Giuseppe Saglio, MD, one of the co-authors on the study and a professor of internal medicine at the University of Turin in Italy, explained that while just 10% of patients who stopped imatinib did so because of side effects, 20% of patients on nilotinib stopped treatment because of side effects.
“So I think, probably, we have to reconsider all this data to suggest which is the best appropriate treatment and particular dosage of the drug as first-line therapy,” Dr Saglio said.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
